Drug Shortages Update – Message from the Canadian Rheumatology Association

  The Canadian Rheumatology Association (CRA) has been recently notified by members across the country of shortages in certain medications that are integral to patient care. The CRA has previously responded to alerts […]

Read More…


Lancet Study: Vaccine Effectiveness Amongst Ontario Patients With Immune-Mediated Inflammatory Diseases

The full article is available here: The Lancet Rheumatology […]

Read More…


Ontario Science Table Guidelines for COVID Treatments & Other Important Links

Please note the following important links: Ontario Science Table Guidelines for COVID Treatments: https://covid19-sciencetable.ca/sciencebrief/clinical-practice-guideline-summary-recommended-drugs-and-biologics-in-adult-patients-with-covid-19-version-10-0/ COVID Assessment Centres: https://covid-19.ontario.ca/covid-19-test-and-testing-location-information#getting-a-clinical-assessment List of Sites Distributing Paxlovid: List of sites distributing Paxlovid – 2022-02-14 (2) […]

Read More…


Actemra (Tocilizumab) Update

Please see the most up to date information on Actemra shortages: Actemra Update […]

Read More…


The Journal of Rheumatology – Board of Directors Position Available

The Journal of Rheumatology is actively seeking to fulfill an open position on its Board of Directors for election at their June 2022 Annual General Meeting. The deadline to apply is January 31, […]

Read More…


Fourth Dose Boosters of COVID-19 Vaccine – Update

It was announced on January 13, 2022, that immunocompromised individuals may begin booking appointments to receive their 4th dose of the COVID-19 vaccine. Here is some information and resources for your reference: – […]

Read More…


Updated MoH Guidelines – Booster Shots for Immunocompromised Patients After Primary Series

On December 14, 2021, the Ministry of Health published updated guidelines on COVID-19 Vaccine Third Dose Recommendations.Highlights of changes:•Immunocompromised individuals who are eligible for a three-dose primary series may receive a booster dose ≥6 months […]

Read More…


CMAJ Article: Projected impact of biosimilar substitution policies on drug use and costs in Ontario

The full article may be viewed via this link: https://www.cmajopen.ca/content/9/4/E1055 […]

Read More…


Long COVID Study – Brain and Cognition Discovery Foundation

The Brain and Cognition Discovery Foundation has announced an ongoing clinical study that may be of interest to patients you provide care for who are experiencing complications from COVID-19. More information is available […]

Read More…


Updated Biosimilar Fact Sheet Reflecting ODB Formulary Changes Effective November 19, 2021

An updated version of the biosimilar fact sheet is available here: Nov 19 Biosimilar-Fact-Sheet […]

Read More…